Pharmacodynamic Trial: Molecular Marker and Imaging Studies as Primary Endpoints to Determine Optimal Biological Dosage of Perifosine, Orally Avail AKT PH Domain Inhibitor Combined w/Docetaxel in Patients w/Relapsed Epithelial Ovarian Cancer.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Docetaxel; Perifosine
- Indications Ovarian cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 13 Jun 2012 Actual patient number is 22 according to ClinicalTrials.gov.
- 13 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 13 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.